The purpose of the study is achieve standardization treatment of low and intermediate risk rhabdomyosarcoma patients, with an attempt to improve treatment results in high and very high risk patients by the addition of doxorubicin as induction treatment and at the maintenance phase.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
event free survival
overall survival
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.